Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

Rhea-AI Summary

Pipeline Therapeutics announced the appointment of Eef Schimmelpennink to its Board of Directors. With nearly 25 years of experience in the biotechnology sector, he aims to enhance the company’s efforts in neuroregeneration. Schimmelpennink has held prominent roles, including CEO of Pfenex and LENZ Therapeutics. His leadership is expected to advance Pipeline's promising portfolio, which includes two clinical candidates, PIPE-307 and PIPE-505, targeting neurological conditions. This strategic addition to the board could bolster the company's growth trajectory in the biopharmaceutical industry.

Positive

• Eef Schimmelpennink's extensive industry experience may drive strategic growth.
• Schimmelpennink's leadership is expected to strengthen Pipeline's neuroregeneration initiatives.

Negative

• Concerns about continuity may arise due to management changes.

SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development.

“I am pleased to welcome Eef Schimmelpennink to Pipeline’s Board of Directors,” said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. “Eef is a renowned leader in the life-sciences industry whose cross-functional leadership experience will be invaluable to Pipeline as we advance our neuroregeneration platform.”

“Pipeline has a very promising portfolio and a strong and thoughtful management team,” said Eef Schimmelpennink. “I welcome the opportunity to join the company on its journey to bring patients new options to address serious neurological disorders.”

Mr. Schimmelpennink currently serves as President and CEO of LENZ Therapeutics, a late-stage clinical company developing innovative ophthalmic pharmaceutical products that aim to improve vision. Prior to LENZ, Mr. Schimmelpennink was CEO and President of Pfenex, Inc. (NYSE: PFNX), up through its acquisition by Ligand Pharmaceuticals in 2020. Before his role at Pfenex, Mr. Schimmelpennink served as CEO for Alvotech, a private specialty biopharmaceutical company. From December 2012 to November 2015, Mr. Schimmelpennink held global marketing and strategy roles at Pfizer and Hospira.

Mr. Schimmelpennink currently serves on the Board of Directors for iBio, Inc. (NYSE:IBIO), where he is the chair of the Nominating and Corporate Governance Committee and a member of the Science and Technology Committee.

Mr. Schimmelpennink obtained his Master of Science in Bioprocess Engineering from Wageningen University & Research, as well as a degree from the Arnhem Business School.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, including remyelination, synaptogenesis and axonal repair. Pipeline has two product candidates in clinical development: PIPE-307, targeting remyelination to treat multiple sclerosis, which recently completed a Phase 1 healthy volunteer study, and PIPE-505, targeting sensorineural hearing loss associated with speech-in-noise disability, which recently completed a Phase 1/2a study. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit www.pipelinetherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005193/en/

Company Contact:

Peter Slover

Chief Financial Officer

ir@pipeline-tx.com

Investor Contact:

Amy Conrad

858-914-1962

amy@juniper-point.com

Source: Pipeline Therapeutics

FAQ

Who is Eef Schimmelpennink and what is his background?

Eef Schimmelpennink is a biotechnology executive with nearly 25 years of experience, previously serving as CEO of Pfenex and currently leading LENZ Therapeutics.

What impact will Eef Schimmelpennink have on Pipeline Therapeutics?

His extensive experience and cross-functional leadership are expected to enhance Pipeline's growth and innovation in neuroregeneration.

What are the key clinical candidates Pipeline Therapeutics is developing?

Pipeline Therapeutics is developing PIPE-307 for multiple sclerosis and PIPE-505 for sensorineural hearing loss.

What role does Eef Schimmelpennink hold at iBio, Inc.?

He serves on the Board of Directors, chairing the Nominating and Corporate Governance Committee and participating in the Science and Technology Committee.